Biohaven navigates mixed clinical trial results amid upcoming data

25 days ago

"Yeah, really incredible move for this company in today's trading session. In the pre-market, it was down something like 12% and now it's up just slightly. It was sinking earlier after a mid-stage study of the company's experimental drug BHV7,000 for the treatment of major depressive disorder missed its primary end point. City said that the data were disappointing, but investors had very low expectations of the study working. According to analyst Samantha Semancow, investors have been more focused on the upcoming latestage epilepsy study data for this company. So that probably made it really easy to kind of shrug off that disappointing study result. The company does not plan on any additional psychiatric clinical trials into 2026."

Biohaven experienced volatile trading after its experimental drug missed a primary endpoint, but investor focus has shifted to upcoming late-stage epilepsy data, with plans for no additional psychiatric trials until 2026.

Related Stocks